REUTERS

Johnson & Johnson: Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression

Originally Published by Johnson & Johnson.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for esketamine nasal spray. Janssen is seeking FDA approval of esketamine for treatment-resistant depression in adults.


Esketamine is an investigational, rapidly acting antidepressant that works differently than currently available therapies for major depressive disorder. Through glutamate receptor modulation, esketamine is thought to help restore connections between brain cells in people with treatment-resistant depression.

“Of the nearly 300 million people who suffer from major depressive disorder worldwide, about one-third do not respond to currently available treatments. This represents a major unmet public health need,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “We are committed to working with the FDA to bring this new treatment option to U.S. patients with treatment-resistant depression and to the medical community.”

The NDA is based on five pivotal Phase 3 studies of esketamine nasal spray in patients with treatment-resistant depression: three short-term studies, one withdrawal maintenance of effect study, and one long-term safety study. Data from these studies demonstrate that treatment with esketamine nasal spray plus a newly initiated oral antidepressant compared to placebo nasal spray plus a newly initiated antidepressant was associated with rapid reduction of depressive symptoms and delayed time to relapse of symptoms of depression. The long-term safety study showed that the esketamine doses studied were generally tolerated, with no new safety signals with dosing up to 52 weeks, compared to data from the short-term esketamine studies.7 The short-term esketamine Phase 3 study in adults with treatment-resistant depression included a newly initiated oral antidepressant in both the control and placebo groups.

“Esketamine has been shown to target critical aspects of glutamate-mediated synaptic plasticity, thereby bringing about rapid and sustained improvement in people with treatment-resistant depression,” said Husseini K. Manji, MD, Global Head, Neuroscience Therapeutic Area, Janssen Research & Development, LLC.

Synaptic plasticity refers to the strength of information that flows through synapses, the spaces where neurons, cells in the brain, are connected.

Esketamine nasal spray will be self-administered by patients under the supervision of health care professionals.

The U.S. FDA granted Breakthrough Therapy Designations for esketamine nasal spray for treatment-resistant depression and for a second indication, major depressive disorder with imminent risk for suicide.8 Janssen is currently conducting Phase 3 clinical studies for the second indication.

Janssen plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the esketamine treatment-resistant depression indication later in 2018.

More information on the esketamine Phase 3 study results can be accessed via the following links:

Latest News

Melanie Willingham-Jaggers

People on the Move: Melanie Willingham-Jaggers, New Executive Director of LGBTQ Advocacy Group GLSEN

The nationwide LGBTQ+ advocacy group Gay, Lesbian and Straight Education Network (GLSEN) has announced the appointment of its new Executive Director, Melanie Willingham-Jaggers. They will be the first Black, nonbinary individual to lead the group in its 32-year history. Founded in 1990 by a group of educators focused on helping…

Walmart interior

Black Corrections Officer Wrongly Accused of Shoplifting in Walmart Claims Store Employees Racially Profiled Him 

Despite Walmart’s ongoing commitment to diversity as an organization, employees at one store in Georgia have been accused of racially profiling one of their customers. Monique Beals of The Hill reported that “David Conners, a Clayton County corrections officer, was stopped and handcuffed by a Fayetteville police officer while he…

Walgreens exterior

Walgreens Planning Virtual Summit To Promote Supplier Diversity

National pharmaceutical giant Walgreens (No. 39 on the DiversityInc Top 50 list) has announced an upcoming supplier diversity summit designed to help the country’s numerous diverse businesses and entrepreneurs promote their businesses and offerings.  Business news site Retail Info Systems (RIS) reported that the virtual event, scheduled for April 5th…

Shane Brown

Las Vegas Police Sued for Jailing Black Man Using an Arrest Warrant Meant for a White Man With a Similar Name

In a case combining mistaken identity, incredibly poor judgment and racial profiling, Las Vegas police are accused of “confusing” a 23-year-old Black man for a white man twice his age simply because they share a similar name. And now that wrongfully detained man is filing suit against the police department…

Olivia Munn

AAPI Forum With Actress Olivia Munn To Discuss Anti-Asian Discrimination Hit with Racist ‘Zoom Bomb’

An online gathering of Asian American women and their allies to talk about anti-Asian discrimination felt the damage firsthand when a racist internet troll attacked their meeting. Leah Asmelash of CNN reported that the “virtual gathering of high-profile Asian American creators, including actress Olivia Munn, became the subject of their…